Effect of Virgin Coconut Oil (VCO) on Cardiometabolic Parameters in Patients with Dyslipidemia: A Randomized, Add-on Placebo-Controlled Clinical Trial

References

• Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–52. doi:10.1016/S0140-6736(04)17018-9.
   PubMed Web of Science ®Google Scholar
• Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR, Bangdiwala S, Tyroler HA. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79(1):8–15. doi:10.1161/01.cir.79.1.8.
   PubMed Web of Science ®Google Scholar
• Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, Boekholdt SM, Khaw K-T, Gudnason V. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007;115(4):450–8. doi:10.1161/CIRCULATIONAHA.106.637793.
   PubMed Web of Science ®Google Scholar
• Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007;298(3):309–16. doi:10.1001/jama.298.3.309.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Merz CNB, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ, American Heart Association, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227–39. doi:10.1161/01.CIR.0000133317.49796.0E.
   PubMed Web of Science ®Google Scholar
• Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S1–S45. doi:10.1161/01.cir.0000437738.63853.7a.
   PubMed Web of Science ®Google Scholar
• Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160(4):459–67. doi:10.1001/archinte.160.4.459.
   PubMed Web of Science ®Google Scholar
• Pearson TA. The undertreatment of LDL-cholesterol: addressing the challenge. Int J Cardiol. 2000;74 Suppl 1(1):S23–S8. doi:10.1016/s0167-5273(99)00108-4.
   PubMedGoogle Scholar
• Velarde GP, Choudhary N, Bravo-Jaimes K, Smotherman C, Sherazi S, Kraemer DF. Effect of atorvastatin on lipogenic, inflammatory and thrombogenic markers in women with the metabolic syndrome. Nutr Metab Cardiovasc Dis. 2021;31(2):634–40. doi:10.1016/j.numecd.2020.10.002.
   PubMed Web of Science ®Google Scholar
• Deedwania P, Murphy SA, Scheen A, Badariene J, Pineda AL, Honarpour N, Keech AC, Sever PS, Pedersen TR, Sabatine MS, et al. Efficacy and safety of PCSK9 inhibition with evolocumab in reducing cardiovascular events in patients with metabolic syndrome receiving statin therapy: secondary analysis from the FOURIER randomized clinical trial. JAMA Cardiol. 2021;6(2):139–47. doi:10.1001/jamacardio.2020.3151.
   PubMed Web of Science ®Google Scholar
• Sampson UK, Fazio S, Linton MF. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep. 2012;14(1):1–10. doi:10.1007/s11883-011-0219-7.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Genest J, Boekholdt SM, Libby P, Gotto AM, Nordestgaard BG, Mora S, MacFadyen JG, Glynn RJ, Kastelein JJP, et al. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet. 2010;376(9738):333–9. doi:10.1016/S0140-6736(10)60713-1.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, Sun S, LeBeaut AP, Sager PT, Veltri EP, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation. 2003;107(19):2409–15. doi:10.1161/01.CIR.0000068312.21969.C8.
   PubMed Web of Science ®Google Scholar
• Davidson MH, Rosenson RS, Maki KC, Nicholls SJ, Ballantyne CM, Mazzone T, Carlson DM, Williams LA, Kelly MT, Camp HS, et al. Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST). Arterioscler Thromb Vasc Biol. 2014;34(6):1298–306. doi:10.1161/ATVBAHA.113.302926.
   PubMed Web of Science ®Google Scholar
• McKenney JM. Combination treatment with atorvastatin plus niacin provides effective control of complex dyslipidemias: a literature review. Postgrad Med. 2012;124(1):7–20. doi:10.3810/pgm.2012.01.2513.
   PubMed Web of Science ®Google Scholar
• Famurewa AC, Ekeleme-Egedigwe CA, Nwali SC, Agbo NN, Obi JN, Ezechukwu GC. Dietary supplementation with virgin coconut oil improves lipid profile and hepatic antioxidant status and has potential benefits on cardiovascular risk indices in normal rats. J Diet Suppl. 2018;15(3):330–42. doi:10.1080/19390211.2017.1346031.
   PubMedGoogle Scholar
• Babu AS, Veluswamy SK, Arena R, Guazzi M, Lavie CJ. Virgin coconut oil and its potential cardioprotective effects. Postgrad Med. 2014;126(7):76–83. doi:10.3810/pgm.2014.11.2835.
   PubMed Web of Science ®Google Scholar
• Famurewa AC, Ejezie FE. Polyphenols isolated from virgin coconut oil attenuate cadmium-induced dyslipidemia and oxidative stress due to their antioxidant properties and potential benefits on cardiovascular risk ratios in rats. Avicenna J Phytomed. 2018;8(1):73–84.
   PubMed Web of Science ®Google Scholar
• Arunima S, Rajamohan T. Virgin coconut oil improves hepatic lipid metabolism in rats–compared with copra oil, olive oil and sunflower oil. Indian J Exp Biol. 2012;50(11):802–9.
   PubMed Web of Science ®Google Scholar
• Nevin KG, Rajamohan T. Beneficial effects of virgin coconut oil on lipid parameters and in vitro LDL oxidation. Clin Biochem. 2004;37(9):830–5. doi:10.1016/j.clinbiochem.2004.04.010.
   PubMed Web of Science ®Google Scholar
• Cardoso DA, Moreira AS, de Oliveira GM, Raggio Luiz R, Rosa G. A coconut extra virgin oil-rich diet increases Hdl cholesterol and decreases waist circumference and body mass in coronary artery disease patients. Nutr Hosp. 2015;32(5):2144–52.
   PubMed Web of Science ®Google Scholar
• Chinwong S, Chinwong D, Mangklabruks A. Daily consumption of virgin coconut oil increases high-density lipoprotein cholesterol levels in healthy volunteers: a randomized crossover trial. Evid Based Complement Alternat Med. 2017;2017:7251562–8. doi:10.1155/2017/7251562.
   PubMed Web of Science ®Google Scholar
• Neelakantan N, Seah JYH, van Dam RM. The effect of coconut oil consumption on cardiovascular risk factors: a systematic review and meta-analysis of clinical trials. Circulation. 2020;141(10):803–14. doi:10.1161/CIRCULATIONAHA.119.043052.
   PubMed Web of Science ®Google Scholar
• Harris M, Hutchins A, Fryda L. The impact of virgin coconut oil and high-oleic safflower oil on body composition, lipids, and inflammatory markers in postmenopausal women. J Med Food. 2017;20(4):345–51. doi:10.1089/jmf.2016.0114.
   PubMed Web of Science ®Google Scholar
• Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K, Daida H, Biro S, Hirobe K, Funahashi T, et al. Diagnostic criteria for dyslipidemia. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb. 2007;14(4):155–8. doi:10.5551/jat.e537.
   PubMed Web of Science ®Google Scholar
• Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB, Gibbons R, Greenland P, Lackland DT, Levy D, O’Donnell CJ, et al. ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S49–S73. 2014doi:10.1161/01.cir.0000437741.48606.98.
   PubMed Web of Science ®Google Scholar
• Yahyavi H, Kaykhaii M, Hashemi M. A rapid spectrofluorimetric method for the determination of malondialdehyde in human plasma after its derivatization with thiobarbituric acid and vortex assisted liquid–liquid microextraction. RSC Adv. 2016;6(3):2361–7. doi:10.1039/C5RA22079C.
   Web of Science ®Google Scholar
• Huang PL. A comprehensive definition for metabolic syndrome. Dis Model Mech. 2009;2(5-6):231–7. doi:10.1242/dmm.001180.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735–52. doi:10.1161/CIRCULATIONAHA.105.169404.
   PubMed Web of Science ®Google Scholar
• St-Onge MP, Bosarge A, Goree LL, Darnell B. Medium chain triglyceride oil consumption as part of a weight loss diet does not lead to an adverse metabolic profile when compared to olive oil. J Am Coll Nutr. 2008;27(5):547–52. doi:10.1080/07315724.2008.10719737.
   PubMed Web of Science ®Google Scholar
• Jadhav HB, Annapure US. Triglycerides of medium-chain fatty acids: a concise review. J Food Sci Technol. 2023;60(8):2143–52. doi:10.1007/s13197-022-05499-w.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu Z, Han Y, Xu J, Huang W, Li Z. Medium Chain Triglycerides enhances exercise endurance through the increased mitochondrial biogenesis and metabolism. PLoS One. 2018;13(2):e0191182. doi:10.1371/journal.pone.0191182.
   PubMed Web of Science ®Google Scholar
• Adeyemi WJ, Olayaki LA, Abdussalam TA, Toriola AP, Olowu AB, Yakub AJ, Raji AO. Investigation of the effects of dietary modification in experimental obesity: low dose of virgin coconut oil has a potent therapeutic value. Biomed Pharmacother. 2020;126:110110. doi:10.1016/j.biopha.2020.110110.
   PubMed Web of Science ®Google Scholar
• Nevin KG, Rajamohan T. Influence of virgin coconut oil on blood coagulation factors, lipid levels and LDL oxidation in cholesterol fed Sprague–Dawley rats. e-SPEN. 2008;3(1):e1–e8. doi:10.1016/j.eclnm.2007.09.003.
   Google Scholar
• Arunima S, Rajamohan T. Effect of virgin coconut oil enriched diet on the antioxidant status and paraoxonase 1 activity in ameliorating the oxidative stress in rats - a comparative study. Food Funct. 2013;4(9):1402–9. doi:10.1039/c3fo60085h.
   PubMed Web of Science ®Google Scholar
• Chen X, Kim DI, Moon HG, Chu M, Lee K. Coconut oil alleviates the oxidative stress-mediated inflammatory response via regulating the mapk pathway in particulate matter-stimulated alveolar macrophages. Molecules. 2022;27(9):2898. doi:10.3390/molecules27092898.
   PubMed Web of Science ®Google Scholar
• Jose SP, K IM, Ratheesh M, Asha S, Sandya S, Rajmohan V. Polyphenolic fraction of virgin coconut oil inhibits the inflammatory response in oxidized LDL activated human peripheral blood mononuclear cells by modulating TLR/NF-κB signaling pathways. Eur J Integr Med. 2017;10:59–65. doi:10.1016/j.eujim.2017.01.004.
   Web of Science ®Google Scholar